Avian Cell, Per Se Patents (Class 435/349)
-
Publication number: 20140154741Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: ApplicationFiled: November 1, 2013Publication date: June 5, 2014Applicant: ValnevaInventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
-
Patent number: 8741653Abstract: The present invention is directed to a modified poxvirus vector that allows for the generation of recombinant poxviruses by a single recombination event. A modified poxvirus vector comprising at least one reporter gene located between two flanking sequences for homologous recombination is disclosed. Furthermore, a host cell comprising said vector and a method for the generation of recombinant poxviruses using said vector are provided.Type: GrantFiled: December 16, 2009Date of Patent: June 3, 2014Assignee: Emergent Product Development GmbHInventors: Sonja Leyrer, Katja Fischer
-
Publication number: 20140127812Abstract: The present invention is long-term cultures of avian PGCs and techniques to produce germline chimeric and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs produce germline chimeric birds. These germline chimeric birds do not have PGC derived somatic cells or tissues. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.Type: ApplicationFiled: December 12, 2013Publication date: May 8, 2014Inventors: Marie-Cecile Van de Lavoir, Philip A. Leighton
-
Publication number: 20140123330Abstract: A genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature. Methods of using, and processes of making, the animals are taught.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Inventors: Daniel F. Carlson, Scott C. Fahrenkrug, Xavier Lauth
-
Publication number: 20140113957Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.Type: ApplicationFiled: June 21, 2012Publication date: April 24, 2014Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin Maier, Klaus Charisse, Rajeev Kallanthottathil, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen Nguyen
-
Publication number: 20140093864Abstract: The present invention relates to a method for improving viability and/or stress tolerance of viable biological material and using the said material comprising applying hydrostatic pressure to said biological material; keeping the said viable biological material at the hydrostatic pressure for a predetermined time period; releasing the hydrostatic pressure; and using the said material for any desired purpose in accordance with any useful protocol. The usage of the said biological material incorporates any techniques, protocols that are applicable in the field of assisted reproductive techniques, biotechnical and/or biotechnological manipulations.Type: ApplicationFiled: October 1, 2012Publication date: April 3, 2014Inventors: Csaba Pribenszky, Miklós Molnár, András Horváth
-
Publication number: 20140086881Abstract: GOOD HEALTHY DRAGON, SNAKE, DIFFERENT SIZE DOUBLE RINGS, LIGHTNING, SQUARE PIXEL, BEAMING RAYS, RECONSTRUCTION BACKGROUND, FACET, CRATER, YELLOW, LEER CELLS were found in New Proteins (among them 27 new ones and their sequences (Under a different patent application) or in the existing discovered proteins and their applications. The process of making the medium derived from any source to harvest any cell—named KH cells—KH cells are good healthy cells in which the RNA synthesizes good proteins that: 1—Send signal to the DAMAGED, SICK, AND BAD CELLS that triggers that synthesis of good proteins that transform these cells to become GOOD healthy cells. 2—Send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being DAMAGED, INFECTED and PRONE to DNA and other cellular alterations.Type: ApplicationFiled: January 31, 2013Publication date: March 27, 2014Inventor: Kieu Hoang
-
Patent number: 8673318Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: November 29, 2012Date of Patent: March 18, 2014Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20140073552Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved stability and/or improved wash performance in any detergent in comparison to their wild type parent enzymes. The enzymes are well-suited for use in any detergent and for some in especially liquid or solid shaped detergent compositions.Type: ApplicationFiled: October 1, 2012Publication date: March 13, 2014Applicants: UNILEVER PLC, NOVOZYMES A/SInventors: Laurens Nicolaas Sierkstra, Jan Klugkist, Peter Markvardsen, Claus Von Der Osten, Peter Bauditz
-
Publication number: 20140068795Abstract: The invention relates to a modified lymphoid cell having gene conversion fully or partially replaced by hypermutation, wherein said cell has no deleterious mutations in genes encoding paralogues and analogues of the RAD51 protein, and wherein said cell is capable of directed and selective genetic diversification of a target nucleic acid by hypermutation or a combination of hypermutation and gene conversion. The invention also relates to a method for diversifying any transgenic target gene in said cell. Preferably, the target gene is integrated into the immunoglobulin light or heavy chain locus by targeted integration.Type: ApplicationFiled: August 2, 2013Publication date: March 6, 2014Inventors: Jean-Marie BUERSTEDDE, Hiroshi ARAKAWA
-
Publication number: 20140068797Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: ApplicationFiled: March 15, 2013Publication date: March 6, 2014Applicants: UNIVERSITY OF VIENNA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jennifer A. Doudna, Martin Jinek, Emmanuelle Charpentier, Krzysztof Chylinski, James Harrison Doudna Cate, Wendell Lim, Lei Qi
-
Publication number: 20140017708Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: September 12, 2013Publication date: January 16, 2014Applicant: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20130336939Abstract: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.Type: ApplicationFiled: January 31, 2012Publication date: December 19, 2013Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, TECHNION RESEARCH AND DEVELOPEMENT FOUNDATION LTD.Inventors: Benjamin Podbilewicz, Ori Avinoam, Judith M. White
-
Publication number: 20130326646Abstract: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.Type: ApplicationFiled: August 8, 2013Publication date: December 5, 2013Applicants: The Trustees of the University of Pennsylvania, The Regents of the University of MichiganInventors: John K. Fink, Shirley Rainer, Robert D. Nicholls, Jinghua Chai
-
Publication number: 20130324440Abstract: The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.Type: ApplicationFiled: January 25, 2012Publication date: December 5, 2013Applicant: Synpromics Ltd.Inventor: Michael L. Roberts
-
Publication number: 20130316404Abstract: The present invention relates to a polypeptide having interleukin-10 function, comprising two interleukin-10 monomer subunits covalently linked by a linker. The present invention further relates to a nucleic acid molecule encoding the polypeptide of the invention, a vector comprising said nucleic acid molecule, a non-human host transformed with the nucleic acid molecule or the vector of the invention as well as a method for the production of a recombinant polypeptide of the invention. The present invention further relates to a pharmaceutical composition as well as to the polypeptide, the nucleic acid molecule, the vector or the host or host cell of the invention for use in treating and/or preventing inflammatory diseases.Type: ApplicationFiled: November 25, 2011Publication date: November 28, 2013Applicants: THE UNIVERSITY OF MANCHESTER, TECHNISCHE UNIVERSITÄT DRESDENInventors: Axel Roers, Sebastian Lanvermann, Werner Müller
-
Publication number: 20130315938Abstract: The current invention is a particle comprising an assembly of lipid-enveloped core polypeptides and transmembrane polypeptides. The transmembrane polypeptides comprise sequences that bind to phagocytes through indirect or direct binding by surface receptors. The result of transmembrane polypeptide binding is engulfment by the phagocyte to low-pH compartments. The low pH triggers a conformational change in transmembrane polypeptides whereby lipids of particles and phagocytes are fused and the contents of the particle, including a polypeptide to be delivered to the cell, are released into the phagocyte.Type: ApplicationFiled: May 25, 2012Publication date: November 28, 2013Inventor: Jeffrey N. Sfakianos
-
Publication number: 20130309747Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.Type: ApplicationFiled: December 9, 2011Publication date: November 21, 2013Inventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
-
Publication number: 20130305397Abstract: This invention relates to a cell comprising a reporter gene under control of an ARIA gene promoter, the cell being used for searching for an agent for prevention or treatment of diseases attributed to reduced insulin sensitivity, for searching for an obesity-controlling substance, or for searching for an obesity-inducing substance.Type: ApplicationFiled: January 20, 2012Publication date: November 14, 2013Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Koji Ikeda, Hiroaki Matsubara, Yoshiki Akakabe
-
Publication number: 20130288364Abstract: The invention provides modified DNA-binding kinetochore polypeptides, wherein the modified DNA binding kinetochore polypeptides comprise a heterologous DNA binding domain. The invention further provides engineered kinetochores containing the modified kinetochore polypeptides. Further provided are artificial chromosomes containing an engineered kinetochore. Cells containing an artificial chromosome containing an engineered kinetochore are also provided. Methods for producing and methods of using the engineered kinetochore, artificial chromosome, and cells are also provided.Type: ApplicationFiled: October 28, 2011Publication date: October 31, 2013Applicant: Whitehead Institute for Biomedical ResearchInventors: Iain Cheeseman, Karen Gascoigne
-
Publication number: 20130273649Abstract: The present invention provides culture media and methods of culturing pluripotent stem cells, such as epiblast stem cells (EpiSCs) and embryonic stem cells (ESCs), in order to culture, derive, and reprogram pluripotent stem cells, such as converting ESCs to EpiSCs.Type: ApplicationFiled: April 12, 2013Publication date: October 17, 2013Applicant: University of Southern CaliforniaInventors: Jun Wu, QiLong Ying, Hoon Kim
-
Publication number: 20130273109Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.Type: ApplicationFiled: April 7, 2011Publication date: October 17, 2013Applicant: NOVARTIS AGInventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20130273021Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: ApplicationFiled: March 11, 2011Publication date: October 17, 2013Applicant: SYNAGEVA BIOPHARMA CORP.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Publication number: 20130261012Abstract: The disclosure relates generally to the targeting of genes to, and their integration into, an immunoglobulin (antibody) heavy chain locus. In particular, the methods described herein contemplate replacing the single rearranged heavy chain V, D, and J genes of a B cell lymphoma such as DT40 with independently rearranged VH-D-JH genes of chicken, in a system for generating immunoglobulin diversity. Also contemplated is replacement of the chicken VH-D-JH with rearranged VH-D-JH genes of other vertebrates including human in a system for generating immunoglobulin diversity, with the exception of any substitution disclosed and claimed in PCT application WO 2009/029315 A2. Also described is construction of a diverse chicken immunoglobulin heavy chain VDJ library in DT40 by homologous gene replacement of the single endogenous rearranged VDJ gene with a chicken VDJ repertoire using the described targeting vectors.Type: ApplicationFiled: March 13, 2013Publication date: October 3, 2013Applicants: University of Washington Through Its Center for Commercialization, OMEROS CORPORATIONInventors: Daniel S. Allison, W. Jason Cummings, John B. Leppard, Nancy Maizels, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
-
Publication number: 20130251693Abstract: Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression.Type: ApplicationFiled: May 22, 2012Publication date: September 26, 2013Applicant: Georiga Health Sciences Univ. Research Inst., Inc.Inventors: YIN-XIONG LI, Michael J. Farrell, Margaret L. Kirby
-
Publication number: 20130251737Abstract: The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: MERIAL LIMITEDInventors: Joyce Pritchard, Teshome Mebatsion, Michel Bublot
-
Publication number: 20130252307Abstract: The invention provides a method for increasing the stability and/or activity of a polypeptide at low pH and/or elevated temperatures. The invention further provides a method for increasing the melting temperature of a polypeptide. Also provided are paleoenzymologically reconstructed thioredoxin polypeptides having activity at higher temperatures and/or lower pH than extant thioredoxin polypepetides, as well as paleoenzymologically reconstructed thioredoxin polypeptides having higher melting temperatures than extant thioredoxin polypepetides.Type: ApplicationFiled: July 15, 2011Publication date: September 26, 2013Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Julio M. Fernandez, Raul Perez-Jimenez, Eric Gaucher, Pallav Kosuri
-
Publication number: 20130243789Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.Type: ApplicationFiled: January 11, 2013Publication date: September 19, 2013Applicant: Abbott LaboratoriesInventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
-
Publication number: 20130243813Abstract: The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine.Type: ApplicationFiled: May 2, 2013Publication date: September 19, 2013Applicant: BAVARIAN NORDIC A/SInventors: PAUL HOWLEY, SONJA LEYRER
-
Publication number: 20130243738Abstract: The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.Type: ApplicationFiled: March 11, 2013Publication date: September 19, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Leigh G. GRIFFITHS, Angeliki PAPALAMPROU, Maelene L. WONG
-
Publication number: 20130244277Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1, wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.Type: ApplicationFiled: March 4, 2013Publication date: September 19, 2013Applicants: UNIVERSITY OF NOTTINGHAM, NOVOZYMES BIOPHARMA DK A/SInventors: Thomas Payne, Darrell Sleep, Christopher John Arthur Finnis, Leslie Robert Evans
-
Publication number: 20130236929Abstract: The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.Type: ApplicationFiled: February 25, 2013Publication date: September 12, 2013Applicant: TRANSGENE S.A.Inventors: Jean-Marc Balloul, Marina Kapfer, Thierry Menguy
-
Publication number: 20130230529Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.Type: ApplicationFiled: January 22, 2013Publication date: September 5, 2013Applicant: The University of Hong KongInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Publication number: 20130216573Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.Type: ApplicationFiled: May 20, 2011Publication date: August 22, 2013Applicant: NOVARTIS AGInventors: Heidi Trusheim, Peter Mason, Michael Franti, Bjoern Keiner, Melissa Sackal, Juerg Hunziker, Francois Natt, David Morrissey
-
Publication number: 20130196430Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: June 12, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
-
Publication number: 20130195871Abstract: Engineered multivalent and multispecific binding proteins that bind two different (e.g., nonoverlapping) epitopes of the same receptor or two different receptors expressed on the same cell are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 28, 2012Publication date: August 1, 2013Applicant: Abbvie Inc.Inventors: Tariq Ghayur, Jijie Gu, Carrie L. Goodreau
-
Publication number: 20130183335Abstract: The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits.Type: ApplicationFiled: October 7, 2011Publication date: July 18, 2013Inventors: Josef Weigl, Jürgen Hausmann, Robin Steigerwald
-
Publication number: 20130171185Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: ApplicationFiled: July 5, 2011Publication date: July 4, 2013Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20130164270Abstract: The present invention relates to engineered polynucleotides and constructs comprising nucleic acid sequences encoding a specific splice-variant (sFLT1-14) of the VEGFR family Flt-1, methods for efficient propagation and expression thereof and compositions and uses thereof. More particularly, the invention relates to isolated polynucleotides comprising a nucleic acid sequence coding for sFlt1-14 or any fragment thereof comprising the serine-rich C-terminus region of said sFlt1-14, wherein at least one of the TCA serine coding codons in said serine-rich C-terminus region of sFlt1-14 as encoded by the nucleic acid sequence of SEQ ID NO. 1, is replaced by any one of TCT, TCC, TCG, AGT, AGC. The invention further provides compositions and method of treating VEGF-associated medical conditions using the polynucleotides of the invention.Type: ApplicationFiled: July 29, 2010Publication date: June 27, 2013Applicant: Yissum Research Developement Company of the Hebrew University of Jerusalem Ltd.Inventors: Eli Keshet, Shay Sela
-
Patent number: 8470598Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: July 9, 2012Date of Patent: June 25, 2013Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20130143265Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.Type: ApplicationFiled: January 14, 2013Publication date: June 6, 2013Applicant: ZymoGenetics, Inc.Inventor: ZymoGenetics, Inc.
-
Publication number: 20130115234Abstract: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.Type: ApplicationFiled: March 28, 2011Publication date: May 9, 2013Applicant: Emergent Product Development Gaithersburg,Inc.Inventors: Tina Guina, Michael Lacy, Mario Skiadopoulos, Nutan Mytle
-
Publication number: 20130117872Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: September 14, 2012Publication date: May 9, 2013Inventors: Subba Reddy PALLI, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
-
Publication number: 20130115635Abstract: Described is an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells that contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing the epitope tag, and uses thereof in affinity-based applications.Type: ApplicationFiled: May 25, 2011Publication date: May 9, 2013Inventors: Els Pardon, Jan Steyaert, Lode Wyns
-
Publication number: 20130115683Abstract: The present invention relates to a method for the preparation of a pharmaceutical composition for the prevention or/and treatment of an influenza virus infection.Type: ApplicationFiled: September 10, 2010Publication date: May 9, 2013Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Nikolaus MACHUY, Alexander KARLAS, Thomas MEYER
-
Publication number: 20130102544Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.Type: ApplicationFiled: December 17, 2012Publication date: April 25, 2013Applicant: Novartis AGInventor: Novartis AG
-
Publication number: 20130095533Abstract: The present invention is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention also discloses polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS derived drug.Type: ApplicationFiled: April 15, 2011Publication date: April 18, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, CLORADO STATE UNIVERSITY RESEARCH FOUNDATION, ALLEGHENY-SINGER RESEARCH INSTITUTEInventors: David H. Sherman, Garth D. Ehrlich, Benjamin Janto, Robert M. Williams, Christopher M. Rath
-
Publication number: 20130095557Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: June 29, 2011Publication date: April 18, 2013Applicant: TRANSGENE S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130089569Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: September 21, 2012Publication date: April 11, 2013Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventor: Helmholtz Zentrum München Deutsches
-
Publication number: 20130074218Abstract: The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: The University of QueenslandInventor: Ian Hector FRAZER